View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsUCB 配当と自社株買い配当金 基準チェック /46UCBは配当を支払う会社で、現在の利回りは1.55%ですが、利益によって十分にカバーされています。前回の支払いは 3rd May, 2023で、権利落ち日は28th April, 2023 。主要情報1.5%配当利回り0.3%バイバック利回り総株主利回り1.8%将来の配当利回り1.8%配当成長2.6%次回配当支払日03 May 23配当落ち日28 Apr 23一株当たり配当金n/a配当性向60%最近の配当と自社株買いの更新UCB SA Proposes DividendFeb 27+ 1 more updateすべての更新を表示Recent updatesUCB Announces Three- and Four-Year Data from Across the Open-Label Extension Phase 3 Trials for BIMZELX®? in Moderate-To-Severe Plaque PsoriasisSep 19UCB Announces Three-Year Data from the BE HEARD Trials for BIMZELXSep 17UCB Announces Results from the Rheum for Improvement SurveySep 10UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency DisorderJun 27UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus ErythematosusJun 12+ 1 more updateUCB SA to Report First Half, 2025 Results on Jul 31, 2025Apr 24UCB Presents Latest Research Across Leading Neurology Portfolio At American Academy of Neurology (AAN) MeetingApr 04+ 1 more updateUCB SA Announces Step Down of Fiona Du Monceau from the Board of DirectorsMar 21UCB Announces Positive Data from Studies Inviding Its Investigational Therapy, Doxecitine and DoxribtimineMar 20Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of Fintepla (Fenfluramine) in Children and Adults with Dravet SyndromeMar 13UCB SA Proposes DividendFeb 27+ 1 more updateUCB’s Bimzelx (bimekizumab) Poised to Disrupt the U.S. Psoriatic Arthritis MarketFeb 15UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis SuppurativaNov 20Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024Nov 15UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic ArthritisOct 01UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024Sep 29UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor LevelsJun 15UCB SA, Annual General Meeting, Apr 24, 2025May 01+ 2 more updatesUCB Announces FDA Accepts Supplemental Biologics License Applications for BimzelxApr 04UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II StudiesMar 09UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual MeetingDec 04UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque PsoriasisNov 15UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid FactorNov 12+ 1 more updateUCB Presents Latest Data from Generalized Myasthenia Gravis PortfolioNov 02UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure ClustersNov 01UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque PsoriasisOct 19UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia GravisOct 18UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023Oct 14UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaOct 13UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024Aug 01Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody PositiveJul 23UCB Announces Resignation of Head of Neurology Solutions Charl Van ZylJun 28+ 1 more updateUCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial SpondyloarthritisJan 19UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023Jan 10UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority ReviewJan 07First half 2022 earnings released Jul 30Investor sentiment deteriorated over the past week Jul 29UCB SA, Annual General Meeting, Apr 27, 2023May 14決済の安定と成長配当データの取得安定した配当: UNCの1株当たり配当金は過去10年間安定しています。増加する配当: UNCの配当金は過去10年間にわたって増加しています。配当利回り対市場UCB 配当利回り対市場UNC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (UNC)1.5%市場下位25% (CH)2.0%市場トップ25% (CH)3.6%業界平均 (Pharmaceuticals)2.8%アナリスト予想 (UNC) (最長3年)1.8%注目すべき配当: UNCの配当金 ( 1.55% ) はSwiss市場の配当金支払者の下位 25% ( 1.98% ) と比べると目立ったものではありません。高配当: UNCの配当金 ( 1.55% ) はSwiss市場の配当金支払者の上位 25% ( 3.6% ) と比較すると低いです。株主への利益配当収益カバレッジ: UNCの配当金は、合理的な 配当性向 ( 60% ) により、利益によって賄われています。株主配当金キャッシュフローカバレッジ: UNCの 現金配当性向 ( 33.7% ) は比較的低く、配当金の支払いはキャッシュフローによって十分にカバーされています。高配当企業の発掘7D1Y7D1Y7D1YCH 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/04/08 07:25終値2023/01/09 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋UCB SA 15 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。38 アナリスト機関Charles PitmanBarclaysCharles PitmanBarclaysBrian BourdotBarclays35 その他のアナリストを表示
UCB Announces Three- and Four-Year Data from Across the Open-Label Extension Phase 3 Trials for BIMZELX®? in Moderate-To-Severe Plaque PsoriasisSep 19
UCB Announces Positive Results from GEMZ Phase 3 Study of Fenfluramine in CDKL5 Deficiency DisorderJun 27
UCB and Biogen Inc. Announces Results from Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol in Systemic Lupus ErythematosusJun 12+ 1 more update
UCB Presents Latest Research Across Leading Neurology Portfolio At American Academy of Neurology (AAN) MeetingApr 04+ 1 more update
UCB Announces Positive Data from Studies Inviding Its Investigational Therapy, Doxecitine and DoxribtimineMar 20
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of Fintepla (Fenfluramine) in Children and Adults with Dravet SyndromeMar 13
UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis SuppurativaNov 20
UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic ArthritisOct 01
UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024Sep 29
UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor LevelsJun 15
UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II StudiesMar 09
UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual MeetingDec 04
UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque PsoriasisNov 15
UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid FactorNov 12+ 1 more update
UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure ClustersNov 01
UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque PsoriasisOct 19
UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia GravisOct 18
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023Oct 14
UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis SuppurativaOct 13
Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody PositiveJul 23
UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial SpondyloarthritisJan 19
UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority ReviewJan 07